These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34801749)

  • 1. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
    Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
    J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
    Shirley M; Keam SJ
    Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
    Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
    J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
    Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Jie W; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Sun C; Wei H; Li C; Ali SM; Miller VA; Wu Q
    J Clin Oncol; 2022 Sep; 40(27):3162-3171. PubMed ID: 35580297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.
    Wang J; Wu L
    Expert Opin Pharmacother; 2022 Apr; 23(6):647-652. PubMed ID: 35272542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
    Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
    J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
    Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
    J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
    Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
    J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
    Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
    J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].
    Yang X; Meng F; Zhong D
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):158-164. PubMed ID: 36872054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
    Yang S; Wu S; Zhao Y; Chen G; Zhu B; Li X; Wang K; Shi J; Cang S; Yao W; Fan Y; Fang J; Zhang L; Zhou J; Wu L; Zheng R; Huang M; Pan Y; Yang Z; Sun M; Yu H; Wang D; Huang J; Wang L; Shu Y; Chen Z; Liu C; Li J; Liu J; Sun S; Guo Y; Meng Z; Liu Z; Han Z; Wu G; Lu H; Ma R; Hu S; Zhao G; Zhang L; Liu Z; Xie C; Zhong D; Zhao H; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Chen Z; Zhuang Z; Guo Z; Greco M; Wang T; Zhou A; Shi Y
    Lung Cancer; 2023 Jun; 180():107194. PubMed ID: 37163774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
    Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
    Deng Y; Yang C; Liu W; Cai S; Guo X
    Anticancer Drugs; 2022 Apr; 33(4):406-412. PubMed ID: 35266890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
    Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
    BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
    Zhang Q; Liu H; Yang J
    Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence.
    Ao L; Fang S; Zhang K; Gao Y; Cui J; Jia W; Shan Y; Zhang J; Wang G; Liu J; Zhou F
    J Exp Clin Cancer Res; 2022 May; 41(1):163. PubMed ID: 35501907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    Shi Y; Zhao Y; Yang S; Zhou J; Zhang L; Chen G; Fang J; Zhu B; Li X; Shu Y; Shi J; Zheng R; Wang D; Yu H; Huang J; Zhuang Z; Wu G; Zhang L; Guo Z; Greco M; Li X; Zhang Y
    J Thorac Oncol; 2022 May; 17(5):708-717. PubMed ID: 35181498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.